Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats.
about
Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone massAngiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidaseLong-term systemic angiotensin II type 1 receptor blockade regulates mRNA expression of dorsomedial medulla renin-angiotensin system componentsAngiotensin II inhibits insulin-stimulated GLUT4 translocation and Akt activation through tyrosine nitration-dependent mechanisms.Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study.Role of the renin-angiotensin system in age-related sarcopenia and diastolic dysfunctionThe effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat.Antihypertensive drugs and glucose metabolismThe effects of the renin-angiotensin-aldosterone system gene polymorphisms on insulin resistance in hypertensive familiesAngiotensin-induced EGF receptor transactivation inhibits insulin signaling in C9 hepatic cells.Oxidative stress and the etiology of insulin resistance and type 2 diabetes.A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA"Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.Inhaled insulin is associated with prolonged enhancement of glucose disposal in muscle and liver in the canine.Molecular mechanism of angiotensin II-induced insulin resistance in aortic vascular smooth muscle cells: roles of Protein Tyrosine Phosphatase-1B.Short-Term Calorie Restriction in Early Life Attenuates the Development of Proteinuria but Not Glucose Intolerance in Type 2 Diabetic OLETF Rats.Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome.Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities.Direct inhibition by angiotensin II of insulin-dependent glucose transport activity in mammalian skeletal muscle involves a ROS-dependent mechanism.Angiotensin receptor blockade increases pancreatic insulin secretion and decreases glucose intolerance during glucose supplementation in a model of metabolic syndrome.Glucoregulatory consequences and cardiorespiratory parameters in rats exposed to chronic-intermittent hypoxia: effects of the duration of exposure and losartan.Telmisartan - killing two birds with one stone.Chronic renin inhibition with aliskiren improves glucose tolerance, insulin sensitivity, and skeletal muscle glucose transport activity in obese Zucker ratsAngiotensin converting enzyme 2: a new important player in the regulation of glycemia.The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.Exploring metabolic dysfunction in chronic kidney disease.International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.Angiotensin-converting enzyme inhibition intervention in elderly persons: effects on body composition and physical performance.Loss of ACE2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice.The renin angiotensin aldosterone system and insulin resistance in humans.Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearanceTherapeutic interventions for hypertension in metabolic syndrome: a comprehensive approach.Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat.Improvement of insulin sensitivity by antagonism of the renin-angiotensin system.Control of adipogenesis by the autocrine interplays between angiotensin 1-7/Mas receptor and angiotensin II/AT1 receptor signaling pathwaysChanges in Angiotensin Receptor Distribution and in Aortic Morphology Are Associated with Blood Pressure Control in Aged Metabolic Syndrome RatsCandesartan cilexetil prevents diet-induced insulin resistance via peroxisome proliferator-activated receptor-γ activation in an obese rat model.
P2860
Q27334866-8C5B1586-ADF7-407E-BABD-98D826E9E23FQ28564620-058DF151-ABE1-4A59-851E-24CF9029FEEAQ28742760-94908C4A-0C31-463F-B258-DB4867185290Q33552248-1391C1AA-012C-486F-B3EB-F0B7EDAA4BC1Q33689466-33E053F1-D82E-4326-AA9E-7857A2EA51FBQ33824351-7F8932DE-EFC0-4642-B32C-11862D0757FBQ33861166-59DFF8C4-2010-46DE-BE24-F9D4A4D0AD59Q33948469-360CF69A-F07E-4C91-88FD-E01B1EDDD84BQ33951289-E7EF8C1E-3FF3-45D2-8CED-3B897AEB1C24Q34180196-8A868569-4833-456F-8490-958151539144Q34768229-6F86F029-3370-48FD-8A05-9515348D75F6Q35072984-F0BDED78-1A20-4FD3-A35B-07E446B54342Q35108463-3532D646-9063-47D3-BF9C-7EE07FB335DAQ35453763-AEE6144D-CD1E-457B-8DC2-EB3CA9E7DCE0Q35659066-70512F8F-5B02-4209-AE2D-B850719872B6Q35684699-B7404324-4202-44C3-91F4-C2B3D4E1EDFBQ35688221-27656471-E899-4ADF-A6F8-B9868CD12726Q35753591-0B31202E-AB5A-420C-9350-F0B0D8C97685Q35764519-660D9F4E-8194-4146-A1FB-892EC6994F7AQ35789287-B6518141-D911-4D58-B17D-3EB9EC1F1407Q35820304-08F2AF09-4FD1-48A6-922C-BCD768346B42Q35872715-011B032A-03BF-490D-907A-481DBB81508FQ35875682-8B9F1D75-CA4F-4FE2-9409-885132AC3972Q35925562-FB96688F-C61A-4F35-9682-02E3D3998D18Q35950287-1692F8E0-A151-449B-AB99-3B9543A4AA90Q36020040-49E8BE38-FA80-4D49-B168-640D5A78CD3FQ36102167-D03B73BE-5530-4AC4-8169-6F99FB0D3765Q36123347-567B82CF-F55F-48E6-BD23-CB8D3BAAB994Q36241932-44C14329-D0A4-4A07-BB08-C9E6AB9F770BQ36242608-D7B062CB-FC11-4473-806C-DA4B2C59DA94Q36336801-A0EE5D12-C704-4A06-8DDA-9C40CEB8CFC5Q36477252-A66989C1-F824-45E0-B912-2CFE8F4F1AB1Q36550987-10EE113B-A87D-4DD4-8542-C0E3C7F70B0FQ36638764-5D77CF7A-6284-49BF-8C42-395E6C022EDDQ36752075-685324AA-531F-45CA-B941-BA7261AE4214Q36805476-C55CD45E-B023-4F87-9022-B68BC782A7CCQ36854401-053676D2-F665-4C7D-9A5A-7A162524D367Q36890554-452695BD-B392-4294-8EDE-B0C12ACBD96BQ36949100-5FF53B11-26A3-4E74-844C-30FD3A7107BAQ37001374-0321717E-ACC9-43E2-A0B8-922BCFD56D9C
P2860
Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Selective angiotensin II recep ...... sistance in obese Zucker rats.
@en
Selective angiotensin II recep ...... sistance in obese Zucker rats.
@nl
type
label
Selective angiotensin II recep ...... sistance in obese Zucker rats.
@en
Selective angiotensin II recep ...... sistance in obese Zucker rats.
@nl
prefLabel
Selective angiotensin II recep ...... sistance in obese Zucker rats.
@en
Selective angiotensin II recep ...... sistance in obese Zucker rats.
@nl
P2093
P356
P1433
P1476
Selective angiotensin II recep ...... sistance in obese Zucker rats.
@en
P2093
E J Henriksen
M K Teachey
T R Kinnick
P304
P356
10.1161/HY1101.092970
P407
P577
2001-10-01T00:00:00Z